Tony Berberabe, MPH, is the Editor for Targeted Therapies in Oncology. Berberabe received his Bachelor of Arts in Biology from Rutgers University and his Master of Public Health from the University of Medicine and Dentistry in New Jersey.
Computer Simulation Helps Plan Transducer Placement in Glioblastoma
October 14th 2016For patients who are likely to experience contiguous recurrence of glioblastoma, a new computer simulation using tumor treating fields (TTF) and employing a personalized transducer array, delivered electric field (EF) intensities that exceeded therapeutic intensities in 3 different tumor locations.
High Rates of Overall Survival Show Benefit of SBRT in Unresectable Liver Cancer
October 14th 2016Results from a phase II study from Korea demonstrated high rates of tumor local control, overall survival (OS), and grade 1/2 gastrointestinal and hepatic toxicities in patients who received stereotactic body radiotherapy (SBRT) for unresectable hepatocellular carcinoma (HCC) after incomplete transarterial chemoembolization (TACE).
Cytoreductive Nephrectomy Improves Survival in RCC
August 15th 2016Patients with renal cancer who underwent cytoreductive nephrectomy (CN) and targeted therapy (TT) had improved survival compared with patients who did not undergo the surgery, according to research from the Dana-Farber Cancer Institute and Brigham and Women’s Hospital.<sup>1</sup> Historically, only 3 in 10 such patients undergo the procedure.
Galeterone Misses PFS Endpoint in Prostate Study, Leading to Trial Discontinuation
July 27th 2016The phase III ARMOR 3-SV trial for prostate cancer was not likely to meet its primary endpoint of radiographic progression-free survival (PFS) improvement, the trial’s independent data monitoring committee (DMC) decided, leading to the trial’s discontinuation, according to the manufacturer Tokai Pharmaceuticals.
Exploring Apalutamide in Patients with High-Risk Prostate Cancer
July 26th 2016A study of apalutamide (ARN-509) in patients with high-risk, localized, or locally advanced prostate cancer who are receiving primary radiation therapy is hoping to reduce the risk of metastasis and death from prostate cancer for these high-risk patients, according to the study’s global principal investigator, Howard M. Sandler, MD.
Apalutamide Investigated in High-Risk Prostate Cancer
June 18th 2016Researchers are hoping the results of a latestage efficacy and safety study of apalutamide (ARN-509) in patients with high-risk, localized, or locally advanced prostate cancer who are receiving primary radiation therapy will demonstrate an improvement in metastasis-free survival, according to global principal investigator, Howard M. Sandler, MD.
Atezolizumab Could be Future First-Line Therapy for Bladder Cancer
June 7th 2016The immunotherapy agent atezolizumab (Tecentriq) reduced the size of tumors by 24% in patients with metastatic urothelial carcinoma (mUC), according to phase II clinical trial results presented at the 2016 ASCO Annual Meeting.
FDA to Review sNDA for Enzalutamide in Metastatic Prostate Cancer
February 24th 2016The FDA has accepted a supplemental new drug application for a capsulated form of enzalutamide for review in patients with metastatic castration-resistant prostate cancer. This application includes findings from the head-to-head studies, TERRAIN and STRIVE.
DNA Repair Defects Vital to PARP Inhibitor's Strength in Prostate Cancer
January 9th 2016A current estimation shows that roughly 25% of metastatic castration-resistant prostate cancers (mCRPC) contain alterations in DNA repair genes. These would normally code for proteins to correct errors arising when cells duplicate their DNA before cell division.
Liquid Biopsy Further Expands Prostate Cancer Treatment Armamentarium
January 5th 2016Resistance to androgen receptor therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) has historically posed a challenge to clinicians. Now, a new blood test that analyzes circulating tumor cells (CTCs) could help overcoming these hurdles.
Checkpoint Inhibitors Could Be the Backbone of Therapy in Advanced Renal Cell Carcinoma
December 30th 2015The programmed cell death 1 (PD-1) and PD-1 ligand (PD-L1) inhibitors "are going to disrupt the current treatment paradigm and will likely be the backbone of combination therapy," said Hans J. Hammers, MD, PhD.
Studies Suggest Radical Prostatectomy May Be Optimal in Men With High-Risk Prostate Cancer
December 3rd 2015Recent studies suggest that RP may be a better initial treatment given many of these patients require multimodal therapy to manage their disease. The question about radiation versus surgery lies in the details, with treatment tailored to each patient.
Dendritic Vaccines Improves Survival in GBM Subset
November 22nd 2015Phase II findings have shown a substantial improvement in overall survival with the dendritic vaccine ICT-107 in a subgroup of patients with HLA-A2+ newly diagnosed glioblastoma multiforme (GBM), warranting further exploration in a phase III study.
Appeal of Physician-Dispensed Abiraterone and Enzalutamide for mCRPC Grows Stronger
November 11th 2015With novel treatments such as abiraterone acetate (Zytiga) and enzalutamide (Xtandi) emerging and financial challenges of diminished reimbursement faced by urology practices mounting, urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer (mCRPC) patients.
First Trial to Show Adjuvant Therapy Benefit in Prostate Cancer Revealed
June 5th 2015In the first phase III trial to show a benefit for adjuvant therapy in prostate cancer, treatment with an adjuvant combination of docetaxel, androgen deprivation therapy (ADT), and radiation therapy (RT) improved 4-year overall survival (OS) rates in patients with high-risk localized prostate cancer, when compared with ADT plus RT alone.
Study Illuminates Role of AR-V7 in Carcinogenesis
May 21st 2015The role of androgen receptor variant-7 in patients with early stage prostate cancer is not well characterized but data presented at the 2015 American Urological Association Meeting by Tyler M. Bauman, BS, is bringing the discussion into focus.
'Using Common Sense' in Prostate Cancer Screening Debate
April 14th 2015The continuing contentious debate about screening for prostate cancer remains top of mind among the public and lay press, but, Leonard G. Gomella, MD, says the decision to screen or not to screen boils down to “using common sense.â€